HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Turnaround Lagging, Vitamin Shoppe Heeds Hedge Fund Direction

This article was originally published in The Rose Sheet

Executive Summary

Shah Capital Management, with 17.7% of Vitamin Shopper shares, and Vintage Capital Management , which owns 14.8%, will appoint three of five replacements to Vitamin Shoppe's board and will have a say in the other two. Vitamin Shoppe also will sell its under-performing contract manufacturing unit and tender, subject to ratification by Shah and Vintage, up to $25m of its common stock at a per-share price not to exceed $5.

You may also be interested in...

P&G Adds Merck's Brands, Expands Consumer Health Categories, Footprint

P&G’s planned purchase of Merck KGaA’s consumer health care business will grow its personal health portfolio 50%, expand its OTC drug and supplement business abroad and open up new categories. CEO David Taylor framed the acquisition as another step in the firm's ongoing portfolio shakeup.

Vitamin Shoppe CEO's Consumer Engagement Fails To Engage Growth, Board Disengages Him From Helm

GNC's New Partner Brings China Access And Funding, Takes Board Seats

As GNC reports substantially trimming its net losses in its 2017 fourth-quarter and full-year results, it announces Harbin Pharmaceutical will invest around $300m in GNC, becoming the single largest shareholder, and the two firms will form a JV for manufacturing, marketing and distributing GNC-branded products in China. With the investment, GNC's board expands from six to 11 members, comprising GNC CEO Ken Martindale, five appointed by Harbin and five by GNC.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts